← Back to Screener
Evotec SE American Depositary Shares (EVO)
Price$3.15
Favorite Metrics
Price vs S&P 500 (26W)-25.27%
Price vs S&P 500 (4W)21.37%
Market Capitalization$1.18B
All Metrics
P/CF (Annual)45.82x
Book Value / Share (Quarterly)$5.40
P/TBV (Annual)1.24x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)1.61%
Cash Flow / Share (Quarterly)$-0.61
Price vs S&P 500 (YTD)0.12%
Gross Margin (TTM)14.49%
Net Profit Margin (TTM)-13.13%
EPS (TTM)$-0.69
10-Day Avg Trading Volume1.07M
EPS Excl Extra (TTM)$-0.69
Revenue Growth (5Y)9.49%
EPS (Annual)$-0.69
ROI (Annual)-8.21%
Gross Margin (Annual)14.49%
Net Profit Margin (5Y Avg)-7.40%
Cash / Share (Quarterly)$3.30
Revenue Growth QoQ (YoY)14.49%
ROA (Last FY)-6.04%
Revenue Growth TTM (YoY)-1.08%
EBITD / Share (TTM)$-0.50
ROE (5Y Avg)-7.99%
Operating Margin (TTM)-7.13%
Cash Flow / Share (Annual)$-0.61
P/B Ratio1.23x
P/B Ratio (Quarterly)1.19x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)1.31x
Net Interest Coverage (TTM)-6.37x
ROA (TTM)-5.72%
EV / EBITDA (TTM)110.22x
EPS Incl Extra (Annual)$-0.69
Current Ratio (Annual)2.07x
Quick Ratio (Quarterly)1.91x
3-Month Avg Trading Volume0.87M
52-Week Price Return-11.82%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$3.38
P/S Ratio (Annual)1.27x
Asset Turnover (Annual)0.46x
52-Week High$8.57
Operating Margin (5Y Avg)-4.57%
EPS Excl Extra (Annual)$-0.69
CapEx CAGR (5Y)-3.57%
Tangible BV CAGR (5Y)4.54%
26-Week Price Return-16.52%
Quick Ratio (Annual)1.96x
13-Week Price Return-10.84%
Total Debt / Equity (Annual)0.55x
Current Ratio (Quarterly)2.07x
Enterprise Value$1,214.423
Revenue / Share Growth (5Y)6.38%
Asset Turnover (TTM)0.44x
Book Value / Share Growth (5Y)0.71%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)22.31x
Pretax Margin (Annual)-11.01%
Cash / Share (Annual)$3.30
3-Month Return Std Dev61.37%
Gross Margin (5Y Avg)19.80%
Net Income / Employee (TTM)$-0
EBITDA Interim CAGR (5Y)20.02%
ROE (Last FY)-12.72%
Net Interest Coverage (Annual)-2.61x
EPS Basic Excl Extra (Annual)$-0.69
P/FCF (TTM)19.72x
Receivables Turnover (TTM)4.83x
Total Debt / Equity (Quarterly)0.55x
EPS Incl Extra (TTM)$-0.69
Receivables Turnover (Annual)4.83x
ROI (TTM)-7.89%
P/S Ratio (TTM)1.27x
Pretax Margin (5Y Avg)-5.56%
Revenue / Share (Annual)$5.23
Tangible BV / Share (Annual)$5.19
Price vs S&P 500 (52W)-46.91%
Year-to-Date Return3.49%
5-Day Price Return20.00%
EPS Normalized (Annual)$-0.69
ROA (5Y Avg)-3.63%
Net Profit Margin (Annual)-13.13%
Month-to-Date Return31.47%
EBITD / Share (Annual)$-0.17
Operating Margin (Annual)-7.13%
LT Debt / Equity (Annual)0.24x
P/CF (TTM)592.09x
ROI (5Y Avg)-5.22%
LT Debt / Equity (Quarterly)0.42x
EPS Basic Excl Extra (TTM)$-0.69
P/TBV (Quarterly)1.90x
P/B Ratio (Annual)1.19x
Inventory Turnover (TTM)22.31x
Pretax Margin (TTM)-11.01%
Book Value / Share (Annual)$5.40
Price vs S&P 500 (13W)-13.71%
Beta1.44x
P/FCF (Annual)40.96x
Revenue / Share (TTM)$5.23
ROE (TTM)-12.28%
52-Week Low$4.00
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
EVOEvotec SE American Depositary Shares | 1.27x | -1.08% | 14.49% | — | $3.15 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Evotec is a drug discovery and contract development and manufacturing organization (CDMO) that partners with pharmaceutical, biotechnology, and academic organizations across multiple therapeutic areas including oncology, central nervous system disorders, and infectious diseases. The company operates through two main segments: Shared R&D services (approximately 80% of revenue), which provides drug discovery, development, and manufacturing on both fee-for-service and collaboration-based models, and Just-Evotec Biologics (approximately 20% of revenue), which offers CDMO services for biologics. With over 5,000 employees and 18 production sites across Europe and the United States, Evotec serves as an integrated partner throughout the drug development lifecycle.